|
Receptor tyrosine kinase
|
Urothelial carcinoma tumors n (%)
|
Urothelial carcinoma cell lines n (%)
|
|---|
|
PDGFRa
|
1 (11%)
|
1 (25%)
|
|
PDGFRb
|
3 (33%)
|
1 (25%)
|
|
KIT
|
3 (33%)
|
1 (25%)
|
|
Flt-3
|
2 (22%)
|
0 (0%)
|
|
M-CSF R
|
3 (33%)
|
1 (25%)
|
|
VEGFR1
|
2 (22%)
|
0 (0%)
|
|
VEGFR2
|
3 (33%)
|
0 (0%)
|
|
VEGFR3
|
5 (56%)
|
0 (0%)
|
|
EGFR
|
9 (100%)
|
4 (100%)
|
|
ErbB2
|
8 (89%)
|
4 (100%)
|
|
ErbB3
|
3 (33%)
|
2 (50%)
|
|
ErbB4
|
4 (44%)
|
1 (25%)
|
|
FGFR1
|
4 (44%)
|
1 (25%)
|
|
FGFR2
|
4 (44%)
|
1 (25%)
|
|
FGFR3
|
4 (44%)
|
1 (25%)
|
|
FGFR4
|
2 (22%)
|
0 (0%)
|
|
Insulin R
|
7 (78%)
|
2 (50%)
|
|
c-RET
|
3 (33%)
|
1 (25%)
|
|
ROR1
|
8 (89%)
|
4 (100%)
|
|
ROR2
|
8 (89%)
|
3 (75%)
|
|
Tie-1
|
9 (100%)
|
4 (100%)
|
|
Tie-2
|
7 (78%)
|
3 (75%)
|
- The 22 most commonly observed phosphorylated receptor tyrosine kinases on the phospho-RTK Arrays are listed in the first column. The number of primary urothelial carcinoma tumors with the respective phosphorylated RTK is shown as a total and percentage of all tumors (n = 9). The number of primary urothelial carcinoma cell lines with the respective phosphorylated RTK is shown in the right column as a total and percentage of all cell lines (n = 5)
